Background: Effective communication of risks and benefits to patients is critical for shared
decision making. Purpose: To review the comparative effectiveness of methods of …

Objective: Although regulatory authorities evaluate the risks and benefits of any new drug
therapy during the new drug‐approval process, quantitative risk–benefit assessment (RBA) …

Decisions regarding the development, regulation, sale, and utilization of pharmaceutical and
medical interventions require an evaluation of the balance between benefits and risks. Such …

Objective: The aim of this study is to estimate the willingness of multiple sclerosis (MS)
patients to accept life-threatening adverse event risks in exchange for improvements in their …

Abstract Discrete Choice Experiments (DCEs) are widely employed survey-based methods
to assess preferences for healthcare services and products. While they offer an experimental …

This study applies conjoint analysis to estimate health-related benefit-risk tradeoffs in a non-
expected-utility framework. We demonstrate how this method can be used to test for and …

Background Gastroprotective agents (GPA) substantially reduce morbidity and mortality with
long‐term nonsteroidal anti‐inflammatory drugs (NSAID s) and aspirin. Objective To …

Benefit-risk assessment is at the centre of the approval process for every new medicine. The
ability to assess the risks of a new medicine accurately and to balance these against the …

Inflammatory bowel disease (IBD), consisting of both Crohn's disease (CD) and ulcerative
colitis (UC), are chronic inflammatory conditions of the intestinal tract. As there is no cure for …

The value of quantitative patient preferences in regulatory benefit-risk assessment Page 1
SHORT COMMUNICATION The value of quantitative patient preferences in regulatory …